Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of cefepime-zidebactam vs meropenem in complicated urinary tract infection or acute pyelonephritis
2019-002768-28Phase 3Completed
- Sponsor
- Wockhardt
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cefepime + zidebactam in complicated urinary tract infection (cUTI), acute pyelonephritis and Symptomatic Bacteriuria (2 arms), sponsored by Wockhardt. Primary endpoint: Overall outcome at Test-of-Cure (TOC). Started Nov 2021; status: completed.
02
Drugs
cefepime + zidebactam
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritisSymptomatic Bacteriuria
Beyond the preview
Go deeper on 2019-002768-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002768-28.